Top Markets
#1 Black Phoenix Black Phoenix +166.30%
#2 Islamic Coin Islamic Coin +157.87%
#3 Glidr Glidr +85.63%
#4 Acurast Acurast +35.71%
#5 Cryptopia Cryptopia +21.79%
#6 Quantum Resistant Ledger Quantum Resistant Ledger +19.81%
#7 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.42%
#8 Wrapped Bitcoin (PulseChain) Wrapped Bitcoin (PulseChain) +16.73%
#9 DOVU DOVU +15.10%
#10 OVERTAKE OVERTAKE +11.32%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Entia Biosciences, Inc. Entia Biosciences, Inc.

Entia Biosciences, Inc.

ERGO
Rank in Stocks #41967
Entia Biosciences, Inc. engages in the development, production, and... Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound for the improvement of iron homeostasis and mitigation of iron-related disorders presenting in anemia, chronic kidney disease, and select neurodegenerative diseases. It is also involved in the discovery, scientific evaluation, and marketing of natural formulations that can be used in medical food, nutraceuticals, cosmetics, and other products. In addition, the company offers beauty products under the GROH brand name. It markets its products directly to consumers through e-commerce channels, such as direct email marketing, social media outlets, and e-commerce sites. The company was formerly known as Total Nutraceutical Solutions, Inc. and changed its name to Entia Biosciences, Inc. in January 2012. Entia Biosciences, Inc. was incorporated in 2007 and is headquartered in Sherwood, Oregon.
Share Price
$0.0002
Last synced: 2026-08-11
Market Cap
$6.73K
Change (1 day)
0.00%
Change (1 year)
100.00%
Country
US
Trade Entia Biosciences, Inc. (ERGO)

Category

Healthcare
P/E ratio for Entia Biosciences, Inc. (ERGO)
P/E ratio as of 2026 TTM: 0
According to Entia Biosciences, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Entia Biosciences, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Royalty Pharma plc Royalty Pharma plc
Royalty Pharma plc
RPRX.US
 23.71 -
US
Swedish Orphan Biovitrum AB Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB
SOBI.ST
 - -
SE
Ipsen S.A. Ipsen S.A.
Ipsen S.A.
IPN.PA
 - -
FR
Recordati Industria Chimica e Farmaceutica S.p.A. Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati Industria Chimica e Farmaceutica S.p.A.
REC.MI
 - -
IT
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated
CORT.US
 220.17 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.